CD274 and non-small cell lung carcinoma: The study of non-squamous NSCLC with PD-L1 expression≥50% reported a slightly lower ICER for first-line Pembro+Chemo vs first-line Pembro ($147,365 per QALY vs $169,335 QALY, respectively) (Insinga et al., 2018).